Ireland-headquartered Allergan (NYSE: AGN) has inked an agreement to acquire ForSight VISION5, a privately-held, clinical-stage biotechnology company focused on eye care.
Under the terms of the agreement, Allergan will acquire ForSight for a $95 million upfront payment and a launch milestone payment related to ForSight's lead development program, a peri-ocular ring designed for extended drug delivery and reducing elevated intraocular pressure (IOP) in glaucoma patients.
The transaction is subject to the satisfaction of customary closing conditions and is expected to be completed within 60 days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze